Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Purine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | FDPS | P14324 | 2/20 | 0.33 |
| ▸ | PI4KA | P42356 | 2/20 | 0.32 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.32 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.32 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | XDH | P47989 | 1/20 | 0.32 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.32 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 2/20 | 0.32 |
| ▸ | G6PD | P11413 | 1/20 | 0.32 |
| ▸ | METAP2 | P50579 | 1/20 | 0.31 |
| ▸ | METAP1 | P53582 | 1/20 | 0.31 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Purine SCHEMBL5989434 | 1.00 | ALDH1A1 (0.39) | ALDH1A1KDM4ERXFP1FDPSPI4KA | |
| Purine SCHEMBL27554272 | 1.00 | ALDH1A1 (0.39) | ALDH1A1KDM4ERXFP1FDPSPI4KA | |
| Purine SCHEMBL2676962 | 0.93 | ALDH1A1 (0.41) | ALDH1A1KDM4ERXFP1FDPSPI4KA | |
| Purine SCHEMBL7453138 | 0.91 | ALDH1A1 (0.33) | ALDH1A1KDM4ERXFP1 | |
| Purine SCHEMBL7453075 | 0.91 | ALDH1A1 (0.33) | ALDH1A1KDM4ERXFP1 | |
| Pyrophosphoric Acid SCHEMBL637333 | 0.90 | ALDH1A1 (0.35) | ALDH1A1KDM4ERXFP1FDPSNTRK1 | |
| Purine SCHEMBL28271 | 0.89 | ALDH1A1 (0.39) | ALDH1A1KDM4ERXFP1PI4KAPI4K2B | |
| Purine SCHEMBL28164598 | 0.88 | ALDH1A1 (0.44) | ALDH1A1KDM4ERXFP1PI4KAPI4K2B | |
| Purine SCHEMBL2120554 | 0.88 | ALDH1A1 (0.47) | ALDH1A1KDM4ERXFP1PI4KAPI4K2B | |
| Purine SCHEMBL3158 | 0.88 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2812441-A1 | NUCLEIC ACID LIGATION METHOD | Wisconsin Alumni Research Foundation (US) | 2014-12-17 | — | — | EP | claimed |
| WO-2013119690-A1 | NUCLEIC ACID LIGATION METHOD | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-08-15 | — | — | WO | claimed |
| US-20130203635-A1 | NUCLEIC ACID LIGATION METHOD | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2013-08-08 | — | — | US | claimed |
| CN-108472371-B | EGFR antibody-drug conjugate and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2022-05-24 | — | — | CN | disclosed |
| US-8981078-B2 | Selective inhibitors of translesion DNA replication | CASE WESTERN RESERVE UNIVERSITY (US) | 2015-03-17 | — | — | US | disclosed |
| EP-2812441-A1 | NUCLEIC ACID LIGATION METHOD | Wisconsin Alumni Research Foundation (US) | 2014-12-17 | — | — | EP | disclosed |
| EP-2812441-A1 | NUCLEIC ACID LIGATION METHOD | Wisconsin Alumni Research Foundation (US) | 2014-12-17 | — | — | EP | disclosed |
| WO-2013119690-A1 | NUCLEIC ACID LIGATION METHOD | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-08-15 | — | — | WO | disclosed |
| WO-2013119690-A1 | NUCLEIC ACID LIGATION METHOD | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-08-15 | — | — | WO | disclosed |
| US-20130203635-A1 | NUCLEIC ACID LIGATION METHOD | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2013-08-08 | — | — | US | disclosed |
| US-20130203635-A1 | NUCLEIC ACID LIGATION METHOD | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2013-08-08 | — | — | US | disclosed |
| US-20130004945-A1 | SELECTIVE INHIBITORS OF TRANSLESION DNA REPLICATION | BERDIS ANTHONY J (US) | 2013-01-03 | — | — | US | disclosed |
| US-8114847-B2 | Selective inhibitors of translesion DNA replication | CASE WESTERN RESERVE UNIVERSITY (US) | 2012-02-14 | — | — | US | disclosed |
| US-20090048202-A1 | SELECTIVE INHIBITORS OF TRANSLESION DNA REPLICATION | CASE WESTERN RESERVE UNIVERSITY | 2009-02-19 | — | — | US | disclosed |
| WO-2006101911-A1 | SELECTIVE INHIBITORS OF TRANSLESION DNA REPLICATION | CASE WESTERN RESERVE UNIVERSITY (US) | 2006-09-28 | — | — | WO | disclosed |
| US-20030180396-A1 | Method of effecting phosphorylation in eucaryotic cells using thiamine triphosphate | INSTITUT PASTEUR (FR) | 2003-09-25 | — | — | US | disclosed |
| EP-1229919-A2 | A METHOD OF EFFECTING PHOSPHORYLATION IN EUCARYOTIC CELLS USING THIAMINE TRIPHOSPHATE | INSTITUT PASTEUR (FR) | 2002-08-14 | — | — | EP | disclosed |
| US-6380169-B1 | FOR INHIBITING MESSENGER RNA TRANSLATION USING ANTI-SENSE OLIGONUCLEOSIDES CONTAINING 5'-CAP CLEAVAGE MOIETIES | ISIS PHARMACEUTICALS, INC. | 2002-04-30 | — | — | US | disclosed |
| WO-2001010444-A2 | A METHOD OF EFFECTING PHOSPHORYLATION IN EUCARYOTIC CELLS USING THIAMINE TRIPHOSPHATE | INSTITUT PASTEUR (FR) | 2001-02-15 | — | — | WO | disclosed |
| WO-1996006621-A1 | METAL COMPLEX CONTAINING OLIGONUCLEOSIDE CLEAVAGE COMPOUNDS AND THERAPIES | GENTA INCORPORATED (US) | 1996-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048202-A1 | SELECTIVE INHIBITORS OF TRANSLESION DNA REPLICATION | REV1, PCNA, DNA2 | ALDH1A1 3867/4885KDM4E 1700/4885RXFP1 4576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.